GenomeWeb January 12, 2022
Staff reporter

NEW YORK – The 40th Annual JP Morgan Healthcare Conference is being held virtually this week due to the ongoing coronavirus pandemic. The first day was very busy for firms operating in the diagnostics and genomic tools markets, and our coverage of those presentations can be found here.

Below are brief reports on individual presentations webcast by the companies or through the JP Morgan conference portal on day two.

Thermo Fisher Scientific

Thermo Fisher Scientific President, Chairman, and CEO Marc Casper highlighted the upsides of the firm’s $24 billion in recent acquisitions, including PPD, Mesa Biotech, Combinati, and others, adding cell sorting technologies as well as rapid and digital PCR systems to the firm’s portfolio.

The...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Medical Devices, Pharma, Pharma / Biotech, Trends
Related Articles:
Cullinan Nets $280M Investment and Targets CD19 in Lupus
Eli Lilly Shows Obesity Drug Zepbound Can Treat Sleep Apnea Too
Fierce Biotech Layoff Tracker 2024: Ultimovacs says goodbye to 40% of staff; Major pharmas turn to layoffs
Lilly's Prevail walks away from Precision gene editing collab
Eli Lilly's tirzepatide scores again, this time in 2 sleep apnea trials

Share This Article